LFG
VERV

Larson Financial Group’s Verve Therapeutics VERV Stock Holding History

Larson Financial Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-60
Closed -$274 – 3508
2025
Q1 		$274 Sell
60
-63
-51% -$422 ﹤0.01% 2718
2024
Q4 		$694 Buy
123
+72
+141% +$406 ﹤0.01% 2123
2024
Q3 		$247 Sell
51
-209
-80% -$1.21K ﹤0.01% 2301
2024
Q2 		$1.27K Buy
+260
New +$1.63K ﹤0.01% 1662

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Larson Financial Group's VERV Position: Q2 2025 in Review

Larson Financial Group sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 60 shares — an estimated $274 sold.

Larson Financial Group first reported a position in VERV in Q2 2024 and held it in 4 quarters. The position peaked at $1.27K in Q2 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Larson Financial Group reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Larson Financial Group sold 60 Verve Therapeutics shares in Q2 2025, an estimated $274.
  • Larson Financial Group first reported a position in Verve Therapeutics in Q2 2024 and held it in 4 quarters.
  • Larson Financial Group's Verve Therapeutics position peaked at $1.27K in Q2 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Larson Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.